Merck Alzheimer’s Drug Advances to Late-Stage Trials

The drug, which is currently the industry’s best hope for treating Alzheimer’s, moves to big trials

Merck & Co. has announced that it will begin big, late-stage trials of its promising experimental drug for Alzheimer’s. According to Reuters, the drug is “one of the industry’s best hopes for slowing the memory-robbing disease.” An independent board assessed the drug’s safety, and suggested the drug be tested on more patients.

The drug, named MK-8931, will move to a Phase III trial that could involve up to 1,960 patients, according to Reuters. The new study is expected to conclude in 2017. In addition to studying the drug’s effects on current Alzheimer’s patients, the study will have trials involving 1,500 patients who do not yet have dementia.

The part of the study done on Alzheimer’s patients is to be called EPOCH, while the part of the study being done on patients who do not yet have the disease will be called APECS. Though not diagnosed with the disease, participants in APECS will have shown mild cognitive problems that could be markers for Alzheimer’s. This part of the study is designed to help researchers know whether or not it’s possible to prevent or slow down the onset of the disease.

MK-8931 is a BACE inhibitor that works by blocking an enzyme called beta secretase that is involved in the production of a protein that creates brain plaques thought to be a major cause of Alzheimer’s, according to Reuters.

Download Center

HTML - No Current Item Deck
  • Safety Management Software - Free Demo

    IndustrySafe Safety Software’s comprehensive suite of modules help organizations to record and manage incidents, inspections, hazards, behavior based safety observations, and much more. Improve safety with an easy to use tool for tracking, notifying and reporting on key safety data.

  • Create Flexible Safety Dashboards

    IndustrySafe’s Dashboard Module allows organizations allows you to easily create and view safety KPIs to help you make informed business decisions. Our best of breed default indicators can also save you valuable time and effort in monitoring safety metrics.

  • Schedule and Record Observations

    IndustrySafe's Observations module allows managers, supervisors, and employees to conduct observations on employees involved in safety critical behavior. IndustrySafe’s pre-built BBS checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Why Is Near Miss Reporting Important?

    A near miss is an accident that's waiting to happen. Learn how to investigate these close calls and prevent more serious incidents from occurring in the future.

  • Get the Ultimate Guide to Safety Training

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common FAQs.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - May 2019

    May 2019

    Featuring:

    • RESPIRATORY PROTECTION
      Why Pick a PAPR? 
    • FIRE SAFETY TRAINING
      Fire Safety: Plan, Prevent, Train, Recover
    • PROTECTIVE APPAREL
      The Truth About Heat Stress and FRC
    • AIHCE EXP 2019 PREVIEW
      Underestimated No More
    View This Issue